3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
The cancer blood test maker could have a bright future.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Agriculture sector binds India-Argentina partnership
Argentine Ambassador Mariano Caucino highlighted the growing economic relationship between Argentina and India during a summit in Mumbai.
The Fed’s building renovations and Trump’s push to oust Powell
- Trump criticized Powell over interest-rate cuts, escalating tensions in 2025
- Fed renovation project cost overruns reached $2.46 billion by 2024
- Powell's successor, Kevin Warsh, confirmed, Fed independence maintained
What we know about the Flydubai flight to Israel
Plane made emergency landing in Saudi Arabia after terrifying fight in cockpit
Fed watchdog finds renovation failures, but no grounds for criminal referral
The long-awaited report by the Fed's inspector general said it found no reasonable grounds to believe federal criminal law had been violated.
Crypto industry gave $8 million to Clarity Act lobbyists who didn't close the deal
In the first half of this year, the sector poured millions into lobbying, with most of it tied to pushing the U.S. market structure bill to a goal it never reached.